Sermorelin

Common side effects:

• Injection site reactions including redness, swelling, or pain
• Flushing or a sudden feeling of warmth
• Mild headaches or transient dizziness
• Nausea or mild gastrointestinal discomfort
• Temporary fatigue or lethargy post-injection

Rare or serious side effects:

• Hyperactivity or unexpected restlessness
• Fluid retention (edema) in the extremities
• Insulin resistance or altered blood glucose levels
• Allergic reactions or anaphylaxis

Receptor activation is the primary mechanism by which the Sermorelin peptide exerts its biological effects. Upon subcutaneous administration, the peptide binds specifically to the growth hormone-releasing hormone receptor (GHRHR) located on the somatotroph cells of the anterior pituitary gland. This binding initiates a signaling cascade involving cyclic AMP (cAMP) and protein kinase A (PKA), which ultimately triggers the synthesis and pulsatile release of endogenous human growth hormone into the systemic circulation.

Feedback regulation distinguishes Sermorelin from exogenous recombinant HGH therapy. Because it relies on the body's intact neuroendocrine axis, Sermorelin is subject to negative feedback loops mediated by somatostatin and insulin-like growth factor 1 (IGF-1). This physiological safeguard prevents the excessive, continuous elevation of growth hormone levels, thereby reducing the risk of tachyphylaxis and minimizing the severe side effects often associated with direct HGH administration Walker RF, 2006.

Discovery and development of Sermorelin began in the 1970s following the isolation and sequencing of natural human growth hormone-releasing hormone (GHRH). Researchers identified that the first 29 amino acids of the naturally occurring 44-amino acid GHRH peptide retained the full biological activity required to stimulate pituitary somatotrophs. This truncated sequence, designated as GRF 1-29 NH2, was synthesized to create Sermorelin, offering a more stable and cost-effective molecule for clinical and diagnostic applications Prakash A, Goa KL, 1999.

Regulatory milestones for Sermorelin include its initial FDA approval in 1997 under the brand name Geref, indicated for the diagnosis and treatment of idiopathic growth hormone deficiency in children. Although the manufacturer voluntarily discontinued Geref in 2008 for commercial rather than safety reasons, the peptide remains widely utilized in research and off-label clinical settings. Today, Sermorelin is frequently investigated in clinical trials for diagnosing adult growth hormone deficiency NCT01060488 and exploring its potential anti-aging and metabolic benefits.